Oncovir, Inc is a pharmaceutical corporation dedicated to the development of nucleic-acid-based clinical therapies for cancer, infectious, immune, and degenerative disorders.

Announcements

Hiltonol (Poly-ICLC) plus Temodar® Treatment of Glioblastoma, A Multicenter Clinical Trial.

January, 2006. Oncovir is pleased to announce the opening of a new multicenter clinical trial to be conducted in collaboration with the prestigious NABTT consortium. Patients with newly diagnosed glioblastoma will be treated with a combination of Hiltonol (Poly-ICLC) and Temodar® chemotherapy. Additional information is available through <www.nabtt.org>.

April, 2003 Hiltonol™ (Poly-ICLC) Treatment of Brain Tumors

Oncovir is cosponsoring two multicenter phase II clinical trials of treatment with its experimental product, Hiltonol™ (poly-ICLC) for patients with malignant brain tumors. The trials are being conducted by the prestigious North American Brain Tumor Consortium (NABTC). Additional information about the trials, including eligibility criteria and locations can be found at www.NABTC.org.

Hiltonol™(Poly-ICLC) Treatment in a Smallpox Model

In a presentation at the International Conference on Antiviral Research in Savannah, Dr. Samuel Baron of Galveston reported marked protection by Hiltonol™ in an otherwise lethal model of disseminated vaccinia poxvirus infection in mice. A single injection of Hiltonol™ provided 80 to 100% protection against mortality due to disseminated virus for as long as 8 days, and a greater than 100-fold inhibition in organ viral load. The vaccinia virus is also the basis of the current smallpox live-virus vaccines, but treatment with Hiltonol™ did not prevent the development of long term immunity to vaccination. The authors infer that treatment with a low, non-toxic dose of Hiltonol™ at the same time as vaccination of humans may provide immediate protection against smallpox and may reduce vaccine complications, while not inhibiting the immune response to vaccination.